SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (617)1/21/1998 1:17:00 AM
From: cape radical  Read Replies (1) | Respond to of 947
 
since when do investors base their valuations exclusively on the balance sheet? i seem to recall that a firm's value is the present value of all of its future free cash flow streams. MSON has cash to invest in growing this business. the key questions to ask are: at what rate will it grow and for how long?

Firm market value = Present value of future free cash flow

and for those of you interested in shareholder value, MSON's ROIC has exceeded its cost of capital.



To: David S. who wrote (617)1/21/1998 9:57:00 AM
From: Wesley0428  Read Replies (1) | Respond to of 947
 
Last FY, MSON generated about $1/share in operating cash flow. At the current price, you could buy the company for about $4.50 a share net of cash on hand. If they only continue to generate $1/share, that's a 22% ROI. Or better yet think of it as a Cash PE of 4.5X.

Looks like a decent value to me.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News